title: [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study].
abstract: OBJECTIVE
  To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS).
  
  
  METHODS
  Case-control study.
  
  
  METHODS
  University Clinic LeonXIII, Medellin, Colombia.
  
  
  METHODS
  We selected from a prevalent population, between 2009-2010, use of clopidogrel patients on an outpatient basis (less than one year and more than 30days), and hospital stay for ACS or the presence of a previous ACS.
  
  
  METHODS
  A case-patient was defined as one who had a recurrence of ACS and a patient-control is defined as one that no recurrence of ACS. Both groups used ambulatory prior clopidogrel due to ACS. As defined risk factor the joint use of omeprazole and clopidogrel outpatients.
  
  
  RESULTS
  During the study, 1680patients clopidogrel formulated. This group identified 50cases readmitted with ACS and 76controls. No statistically significant association was found between use of clopidogrel-omeprazole and increased risk of hospital readmission for ACS (OR: 1.05; 95%CI: 0.516-2.152; P=.8851).
  
  
  CONCLUSIONS
  In this small group of patients with previous SCA, the simultaneous use of clopidogrel with omeprazole does not increase the risk of a readmission by recurrence of this type of coronary event.
authors.affiliation: Grupo de Investigación, Promoción y Prevención Farmacéutica, Facultad de Química Farmacéutica, Universidad de Antioquia, Medellín, Antioquia, Colombia. Electronic address: pamaris@farmacia.udea.edu.co.
authors.forename: Pedro
authors.initials: P
authors.lastname: Amariles
authors.affiliation: Grupo de Investigación, Promoción y Prevención Farmacéutica, Facultad de Química Farmacéutica, Universidad de Antioquia, Medellín, Antioquia, Colombia.
authors.forename: Héctor
authors.initials: H
authors.lastname: Holguín
authors.affiliation: IPS Universitaria León XIII, Facultad de Medicina, Universidad de Antioquia, Medellín, Antioquia, Colombia.
authors.forename: Nancy Yaneth
authors.initials: NY
authors.lastname: Angulo
authors.affiliation: Servicio Farmacéutico, IPS Universitaria León XIII, Medellín, Antioquia, Colombia.
authors.forename: Piedad Maria
authors.initials: PM
authors.lastname: Betancourth
authors.affiliation: Grupo de Investigación, Promoción y Prevención Farmacéutica, Facultad de Química Farmacéutica, Universidad de Antioquia, Medellín, Antioquia, Colombia.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Ceballos
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000453:epidemiology*; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D000077144:Clopidogrel; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D010359:Patient Readmission / Q000706:statistics & numerical data*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D012008:Recurrence; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D009853:Omeprazole; D013988:Ticlopidine
keywords: Acute coronary syndrome; Antiagregación plaquetaria; Antiplatelet effects; Clopidogrel; Drug interactions; Hospital readmission; Interacción medicamentosa; Omeprazol; Omeprazole; Reingreso hospitalario; Síndrome coronario agudo